Gamco Investors INC. ET AL Cuts Stock Holdings in CVS Health Corporation $CVS

Gamco Investors INC. ET AL lowered its position in shares of CVS Health Corporation (NYSE:CVS) by 17.3% in the 1st quarter, Holdings Channel.com reports. The fund owned 93,220 shares of the pharmacy operator’s stock after selling 19,493 shares during the quarter. Gamco Investors INC. ET AL’s holdings in CVS Health were worth $6,695,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. State Street Corp boosted its holdings in CVS Health by 2.1% in the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after purchasing an additional 1,245,457 shares during the last quarter. Legal & General Group Plc raised its stake in CVS Health by 0.3% during the 4th quarter. Legal & General Group Plc now owns 9,309,182 shares of the pharmacy operator’s stock valued at $738,777,000 after buying an additional 31,249 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of CVS Health by 28.4% during the 4th quarter. Deutsche Bank AG now owns 4,666,495 shares of the pharmacy operator’s stock valued at $370,333,000 after buying an additional 1,031,998 shares during the period. KBC Group NV boosted its stake in shares of CVS Health by 200.4% in the 4th quarter. KBC Group NV now owns 676,809 shares of the pharmacy operator’s stock worth $53,711,000 after buying an additional 451,521 shares during the last quarter. Finally, Hussman Strategic Advisors Inc. purchased a new position in shares of CVS Health in the 4th quarter worth $3,333,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CVS has been the subject of a number of research reports. Robert W. Baird upped their price objective on CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Morgan Stanley raised their target price on CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. Barclays upped their price target on shares of CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a research report on Tuesday, May 26th. HSBC reiterated a “hold” rating and issued a $103.00 price objective on shares of CVS Health in a research note on Monday, July 6th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Twenty-one investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $105.67.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is getting a sentiment boost from multiple headlines around its expanded pharmacy services, including nationwide filling of select pet prescriptions and a new service for harder-to-find medications, which could support retail pharmacy traffic and reinforce its convenience-driven growth story.
• Positive Sentiment: Analyst commentary remains constructive, with Zacks calling CVS a top long-term momentum stock and other reports noting a “Moderate Buy” consensus and higher price targets, suggesting Wall Street still sees upside tied to pharmacy, PBM, and Medicare Advantage execution. Article Title
• Positive Sentiment: Options activity also pointed to bullish trading interest, with unusually heavy call buying in CVS, often interpreted as a sign that traders expect further upside or a continued positive trend.
• Neutral Sentiment: A recent report on CVS’s dividend noted that payouts have been unchanged for 10 quarters, framing the dividend as a question for income investors rather than a clear catalyst for the stock.
• Neutral Sentiment: CVS stock has already had a strong run over the past year, and one article highlighted the shares nearing valuation levels that depend heavily on continued operational execution and policy stability.
• Negative Sentiment: Henry Ford Health filed a lawsuit alleging CVS used fraudulent reimbursement practices tied to the 340B drug discount program, which could create legal costs, headline risk, and potential pressure on margins if the claims gain traction. Article Title

Insider Activity

In other CVS Health news, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the transaction, the director directly owned 4,824,799 shares in the company, valued at $450,877,466.55. This represents a 7.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,441,551 shares of company stock valued at $323,703,977 in the last quarter. 0.85% of the stock is currently owned by company insiders.

CVS Health Stock Down 0.1%

Shares of CVS stock opened at $107.64 on Monday. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a one year low of $58.99 and a one year high of $110.68. The company’s fifty day moving average price is $100.21 and its 200-day moving average price is $86.16. The company has a market capitalization of $137.34 billion, a price-to-earnings ratio of 47.42, a PEG ratio of 1.05 and a beta of 0.61.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter in the prior year, the firm posted $2.25 EPS. CVS Health’s quarterly revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts expect that CVS Health Corporation will post 7.46 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd will be paid a $0.665 dividend. The ex-dividend date of this dividend is Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.5%. CVS Health’s dividend payout ratio is 117.18%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.